Détails sur le projet
Description
The FDA has proposed to extend its current error and accident reporting
requirements to all blood collection and transfusion facilities. This
is in response to concerns expressed in recent Office of the Inspector
General reports, congressional hearings and public concerns whether the
current reporting procedures for blood safety events are adequate. The
development and operation of near-miss event reporting systems in other
error critical fields such as aviation and nuclear power represent one
approach to dealing with error. The Medical Event Reporting System for
Transfusion Medicine (MERS-TM) was developed at the University of Texas
Southwestern Medical Center as a reporting system to collect and
classify incidents with the potential for compromising the safety of
blood transfusion. MERS-TM has been implemented in three blood centers
and three hospital based transfusion services. It is proposed that the
MERS-TM project be continued over a four year period of time to meet the
following specific aims: (1) to validate the effectiveness of near-miss
reporting through MERS-TM as a potential national standard for reporting
error and safety hazards in all major blood provider organizations,
including American Red Cross, Blood Systems, Inc., participating members
of America's Blood Centers, and American Blood Resources Association;
(2) to validate MERS-TM as an event reporting standard for hospital-
based transfusion services in a convenience sample of representative
hospitals from across the country; (3) to determine national trends and
unique causal patterns from near-miss incidents and adverse events
through a variety of analysis techniques applied to the MERS-TM
database; (4) to develop and demonstrate analysis techniques that can
be applied to gain further insight to problem areas identified by near-
miss reporting in donor suitability and in transfusion administration;
(5) to evaluate the effectiveness of MERS-TM, document the
implementation process and the impact of MERS-TM on participating
organizations and the field of transfusion medicine.
A strong project staff is in place and there has been a high degree of
consensus among the major organizations in the field that MERS-TM should
be evaluated as a potential national standard for reporting incidents
within the field of transfusion medicine. The validation and continued
operation of MERS-TM is an appropriate response to the public's interest
and to meet the needs of transfusion medicine.
Statut | Terminé |
---|---|
Date de début/de fin réelle | 1/1/95 → 12/31/05 |
Financement
- National Heart, Lung, and Blood Institute: 1 042 214,00 $ US
- National Heart, Lung, and Blood Institute: 932 921,00 $ US
- National Heart, Lung, and Blood Institute: 889 090,00 $ US
Keywords
- Hematología
Empreinte numérique
Explorer les sujets de recherche abordés dans ce projet. Ces étiquettes sont créées en fonction des prix/bourses sous-jacents. Ensemble, ils forment une empreinte numérique unique.